Business Context and Reporting Period
Company: Cardinal Health, Inc. (formerly Cardinal Distribution, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and nine months ended December 31, 1993 (Fiscal Year 1994).
Business Overview: A national distributor of pharmaceutical products and medical supplies. The period was marked by significant growth through internal expansion and acquisitions, most notably the pooling-of-interests merger with Whitmire Distribution Corporation, which was approved by shareholders in January 1994 and effective February 7, 1994.
Key Financial Metrics
| Metric | 3 Months Ended Dec 31, 1993 | 9 Months Ended Dec 31, 1993 | 9 Months Ended Dec 31, 1992 |
|---|---|---|---|
| Net Sales | $657,653 | $1,805,065 | $1,467,640 |
| Gross Margin | $38,012 (5.78%) | $106,453 (5.90%) | $91,092 (6.21%) |
| Operating Earnings | $18,673 | $49,880 | $43,482 |
| Net Earnings | $10,924 | $27,925 | $13,041 |
| Diluted EPS | $0.47 | $1.25 | $0.68 |
| Cash and Equivalents (End of Period) | $52,124 | N/A | |
| Net Cash from Operating Activities (9 Months) | $19,536 | $148,507 | |
| Total Debt (Current + Long-Term) | $110,994 | N/A |
Note: All figures in thousands except per share data.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 29% in the third quarter and 23% for the nine-month period compared to the prior year. Growth was driven by 20% internal growth in the quarter (new customers, expanded territories) and the acquisition of Solomons Company in May 1993.
- Margin Compression: Gross margin percentage declined to 5.78% (Q3) and 5.90% (9 months) from 6.10% and 6.21% respectively. Management attributes this to lower selling margin rates due to a competitive market, a shift to higher-volume customers, and reduced purchasing gains from lower drug price inflation.
- Operating Efficiency: Selling, General & Administrative (SG&A) expenses improved as a percentage of sales, dropping to 2.94% in Q3 from 3.32% last year, due to economies of scale and productivity improvements.
- Debt Reduction: Interest expense decreased significantly ($1.0M in Q3, $2.8M for 9 months) following the conversion of $74.9 million of Subordinated Debentures into common stock in July 1993.
- Cash Flow Volatility: Net cash provided by operating activities dropped to $19.5 million for the nine months ended Dec 31, 1993, compared to $148.5 million in the prior year. This was primarily due to a $99.3 million increase in merchandise inventories and a $36.8 million increase in trade receivables, offset by a $148.1 million increase in accounts payable.
Guidance, Outlook, and Unusual Items
Unusual Items
- Termination Fee: A one-time gain of $13.5 million was recorded in the second quarter of 1993 from the termination of a merger agreement with Durr-Fillauer Medical, Inc.
- Nonrecurring Charges: $9.9 million in charges were recorded in the second quarter of 1993 related to closing non-core operations and rationalizing distribution and information systems.
- Accounting Change: The adoption of SFAS 109 resulted in a cumulative effect charge of $10.0 million, reducing net earnings for the nine-month period.
Outlook and Management Commentary
- Margins: Management expects the decline in selling margin rates to continue in the immediate future but not in the long term.
- Whitmire Merger: The company completed the merger with Whitmire Distribution Corporation (revenues of $2.7 billion) effective February 7, 1994. Pro forma results suggest significant scale, with combined net sales of $4.0 billion for the nine months ended Dec 31, 1993.
- Liquidity: The company maintains $175 million in line-of-credit agreements, none of which were utilized as of December 31, 1993. Management anticipates refinancing Whitmire's $120 million credit agreement and incurring approximately $28 million in merger-related costs.
Risks and Contingencies
- Legal Proceedings: Cardinal and Whitmire are defendants in nine class-action lawsuits regarding alleged price-fixing in brand name prescription drugs. The company intends to contest these vigorously.
Investor Verification Checklist
- Merger Integration: Verify the actual costs and timeline for integrating Whitmire's operations, specifically the projected $28 million in nonrecurring expenses.
- Margin Sustainability: Monitor whether gross margin rates stabilize or continue to compress as the company shifts toward higher-volume, lower-margin customers.
- Working Capital Management: Assess the company's ability to manage the significant increase in inventory and receivables without further straining operating cash flow.
- Legal Exposure: Track the status of the "Brand Name Prescription Drug Litigation" to evaluate potential liability.
- Debt Refinancing: Confirm the terms and interest rates associated with the refinancing of Whitmire's revolving credit agreement.